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ORIGINAL ARTICLE INFECTIOUS DISEASESAssociation between hypoalbuminemia and mortality among subjects
treated with ertapenem versus other carbapenems: prospective cohort
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Rambam Medical Center, Rambam, IsraelAbstractThe aim of this study was to determine whether ertapenem, being highly protein bound, is less effective than other carbapenems in the
presence of hypoalbuminemia. In a prospective cohort study, we included adults with clinically and microbiologically documented
infections caused by carbapenem-susceptible Enterobacteriaceae who were hospitalized in a tertiary medical center from March 2010 to
September 2012. We tested whether hypoalbuminemia (serum albumin <2.5 g/dL) had a larger effect on 30-day mortality in subjects
treated with ertapenem compared to those treated with meropenem or imipenem (I/M). Logistic regression analysis was used to identify
independent risk factors for death including the carbapenem drug and the interaction between albumin and the carbapenem. Of 279
individual subjects included, 173 were treated with ertapenem and 106 with I/M. The odds ratio (OR) for 30-day mortality with
hypoalbuminemia was 4.6 (95% conﬁdence interval (CI) 2.1–10.1) among subjects with ertapenem versus 1.2 (95% CI 0.5–2.70) with I/M
(p = 0.02 for difference between groups). In the regression model, the interaction between carbapenem type and albumin levels was
signiﬁcant (p = 0.03); for ertapenem lower albumin levels were associated with increased 30-day mortality (OR 2.45, 95% CI 1.19–5.05),
while for I/M the change was not signiﬁcant (OR 0.67, 95% CI 0.31–1.41). The model suggests that the risk of death for ertapenem-
treated subjects quintupled when albumin was 2 g/dL compared to 4 g/dL. Hypoalbuminemia was associated with mortality signiﬁcantly
more among subjects treated with ertapenem compared to subjects treated with I/M. The effectiveness of current dosing schemes of
ertapenem in subjects with signiﬁcant hypoalbuminemia should be revisited.
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E-mail: orenzu1@clalit.org.ilIntroductionInvasive infections caused by extended-spectrum β-lactamase
(ESBL)-producing bacteria are common [1–4], and spread into
the community has been documented in recent years [5–7].Microbiol Infect 2015; 21: 54–58
nical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2014.08.003The treatment of choice for these bacteria are the carbapenem
antibiotics [8]. Imipenem, meropenem and ertapenem are
currently the most commonly used carbapenems. While imi-
penem was compared to meropenem in many randomized
controlled trials [9], to our knowledge, ertapenem has not been
compared to the other carbapenems in a randomized design.
Ertapenem is highly protein bound (92–95%), explaining its
long, 4-hour half-life, allowing convenient once-daily dosing
[10,11]. In order to exert maximal bactericidal effect, the active,
unbound fraction needs to exceed the minimum inhibitory
concentration for >40% of the interval [12]. Critically ill sub-
jects and subjects with severe sepsis often haveious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Zusman et al. Ertapenem in sepsis with hypoalbuminemia 55hypoalbuminemia and altered pharmacokinetics [13,14]. With
hypoalbuminemia, there is less protein-bound drug and greater
volume of distribution. Although initially there is a higher
concentration of free, active drug, it is cleared rapidly, resulting
in a smaller reservoir of bound drug. Faster clearance leads to
shorter half-life and overall less drug exposure. Pharmacoki-
netic studies have shown that among critically ill subjects, the
non-protein-bound fraction of ertapenem decreases with
hypoalbuminemia, resulting in lower maximal concentration
and failure to reach the required time over minimum inhibitory
concentration [12,15–17].
We aimed to examine the clinical correlates of hypo-
albuminemia among subjects treated with ertapenem. Our hy-
pothesis was that ertapenem is less efﬁcient when given in
standard dosage in hypoalbuminemic subjects compared to
subjects with higher albumin levels. Because hypoalbuminemia
is independently associated with sepsis severity and mortality
[18], we chose a comparative design, examining the association
between albumin levels and mortality with ertapenem
compared to other carbapenems.MethodsDesign, subjects, settings and inclusion
This prospective, noninterventional cohort study was conducted
fromMarch 2010 to September 2012 at BeilinsonHospital, Rabin
Medical Center. We included subjects fulﬁlling Centers for
Disease Control and Prevention clinical diagnostic criteria [19]
for a microbiologically documented infection caused by Enter-
obacteriaceae susceptible to all carbapenems and treated with
imipenem, meropenem or ertapenem for more than 2 days.
Subjects were included in the study only once, for the ﬁrst in-
fectious episode fulﬁlling inclusion criteria. Subjects with poly-
microbial infections were included, except for those with
concomitant carbapenem-resistant bacteria. Treatment was at
the discretion of the treating physician. The study was approved
by the institution’s ethics committee, and need for signed consent
was waived, given the noninterventional design of the study.
Exposure and outcomes
The exposure was treatment with ertapenem compared with
imipenem or meropenem (I/M), with the primary comparison
subgrouped by albumin levels: 2.5 g/dL (hypoalbuminemia) or
>2.5 g/dL. Ertapenem was administered as a 1-g single daily
dose; meropenem 1–2 g thrice daily and imipenem 500 mg four
times a day for subjects with normal renal function. Doses were
adjusted for renal function, and all drugs were provided as short
bolus infusions. The outcome was all-cause mortality 30 day
after initiation of treatment.Clinical Microbiology and Infection © 2014 European Society of Clinical MicrobioloData collection and variables
Baseline subject characteristics that were collected included age
and sex, comorbid conditions such as heart failure, malignancy,
diabetes, renal and liver failure, chronic pulmonary disease, and
immunosuppression status, Charlson score [20], functional
capacity at hospital admission, duration of hospitalization before
infection onset and invasive procedures before infection onset.
We collected data on the source of infection, place of acqui-
sition, and Sequential Organ Failure Assessment (SOFA) score
[21] at presentation. Data regarding antibiotic treatment pro-
vided throughout the infective episode until day 30 were
collected. Appropriate empirical antibiotic treatment was
deﬁned by in vitro coverage as covering antibiotics administered
within 48 hours of obtaining the index culture.
ESBL production was tested using a ceftazidime (30 μg) and a
combination of ceftazidime/clavulanate (30/10 μg) disks, with a
5-mm difference indicating positivity, following the recom-
mendations of the Clinical and Laboratory Standards Institute
(CLSI) [22]. Antibiotic susceptibility was also determined by
CSLI criteria.
Statistical analysis
Comparison of categorical variables was performed by the chi-
square test. Mortality odds ratios (OR) were calculated by the
Mantel-Haenszel test stratiﬁed by albumin, provided the
Breslow-Day test for homogeneity of odds was signiﬁcant
(p < 0.05). Continuous variables were tested for normality by
the Shapiro-Wilk test, compared by t test or Mann-Whitney U
test, and presented as median and interquartile range (25th–
75th percentiles). All variables signiﬁcantly associated with
mortality on univariate analysis (p < 0.05) were tested and ﬁtted
into a logistic regression model, forcing the interaction between
serum albumin levels (continuous variable) and the carbapenem
type into the analysis. Correlation analysis was conducted
before selection of variables for inclusion in the model to avoid
entry of highly correlated data. Analyses were conducted by
IBM SPSS Statistics 20 software (IBM) and the R language for
statistical computing [23].ResultsTwo hundred seventy-nine subjects fulﬁlled the inclusion
criteria, with 173 subjects receiving ertapenem, 78 meropenem
and 28 imipenem/cilastatin (total of 106 in the I/M group). At
onset of infection, 231/279 (83%) subjects were hospitalized in
medical or surgical wards and 27/279 (10%) in the intensive
care unit; 21/279 (7%) had healthcare-associated infections
acquired out of the hospital. There were signiﬁcant differences
between subjects treated with ertapenem and those treatedgy and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 54–58
TABLE 1. Univariate analysis of all-cause 30-day mortality in
combined study cohort
Characteristic
Dead
n [ 73 (%)
Alive
n [ 206 (%) p
Demographic and comorbid conditions
Age (y) (IQR) 76 (23) 66 (24) <0.01
Female sex 26 (36) 97 (47) 0.12
Previous hospitalization 49 (67) 134 (65) 0.86
Invasive surgical procedure 21 (29) 60 (29) 1
Home dweller 47 (64) 144 (70) 0.47
Functionally dependenta 35 (48) 74 (36) 0.1
Heart failure 13 (18) 26 (13) 0.37
Chronic pulmonary disease 10 (14) 23 (11) 0.72
Diabetes 32 (44) 81 (39) 0.59
Malignancy 20 (27) 52 (25) 0.7
Chronic renal failure 2 (3) 5 (2) 1
Immunosuppression 19 (26) 62 (30) 0.61
Charlson score (IQR) 3 (3) 2 (2) 0.01
Infection characteristics
Infection source
Pneumonia 20 (27) 34 (17) 0.06
Ventilator-associated pneumonia 6 (8) 13 (6) 0.77
Catheter related 2 (3) 9 (4) 0.79
Urinary tract infection 31 (42) 92 (45) 0.85
Meningitis 2 (3) 1 (0) 0.34
Intra-abdominal 8 (11) 19 (9) 0.84
Surgical site 7 (10) 30 (15) 0.38
Skin/soft tissue 9 (12) 23 (11) 0.96
Other/unknown 4 (5) 10 (5) 1
Bacteremia 33 (45) 79 (38) 0.37
ICU stay at index culture 6 (8) 21 (10) 0.62
Invasive mechanical ventilation 18 (25) 29 (14) 0.06
Shockb 10 (14) 13 (6) 0.08
Creatinine (mg/dL)b (IQR) 1.4 (0.8) 1 (1.4) <0.01
Albumin (g/dL)b (IQR) 2.5 (1) 2.9 (1) <0.01
Platelets (×1000/μL)b (IQR) 203 (174) 236 (188) 0.1
Hematocrit (%)b (IQR) 29.6 (7) 30 (7) 0.28
Appropriate empiric therapy 24 (33) 47 (23) 0.12
Carbapenem provided as empiric therapy 29 (40) 100 (48) 0.19
SOFA scoreb (IQR) 5 (5) 3 (4) <0.01
ICU, intensive care unit; SOFA, Sequential Organ Failure Assessment.
aUnable to perform activities of daily living independently.
bVariable measured at onset of sepsis.
TABLE 2. Logistic regression model for mortalitya
Variable
Adjusted OR
(95% CI) p
Intercept (constant) 0.019 <0.01
Age 1.03 (1.01–1.05) 0.04
Charlson score 1.16 (1.01–1.34) 0.07
SOFA score at infection onset 1.25 (1.12–1.38) <0.01
Serum albumin (g/dL)
Ertapenem treated 0.41 (0.20–0.84) 0.01
I/M treated 1.5 (0.71–3.2) 0.26
Serum albumin (g/dL) by use of carbapenem 3.7 (1.4–10.09) 0.02
OR, odds ratio; CI, conﬁdence interval; SOFA, Sequential Organ Failure
Assessment; I/M, meropenem or imipenem.
a2 log likelihood 263; Hosmer-Lemeshow p = 0.65.
56 Clinical Microbiology and Infection, Volume 21 Number 1, January 2015 CMIwith I/M regarding baseline characteristics, sources of infection,
sepsis presentation and empirical treatment (Supplementary
Table 1). Ertapenem was used more frequently in older
women, subjects who were functionally dependent and those
with urinary tract infections. I/M-treated subjects had higher
SOFA score at baseline. Subjects treated with ertapenem
received inappropriate empirical antibiotic treatment more
frequently. Bacteremia was present in 40% of subjects, with no
difference between groups. Escherichia coli was isolated in 34
(33%) subjects in the I/M group and 91 (53%) in the ertapenem
group (p = 0.001), while Klebsiella spp. were isolated in 50
(51%) and 51 (29%), respectively (p = 0.002). Other Enter-
obacteriaceae were equally distributed. Infections were caused
by ESBL-positive bacteria in 151 (87%) of subjects treated with
ertapenem versus 73 (69%) of subjects treatment with I/M
(p < 0.001).
Carbapenem dosing information is presented in
Supplementary Table 2.
A concomitant or subsequent microbiologically documented
infection was documented in 61 (35%) and 40 (38%) subjects
treated with ertapenem and I/M, respectively. An additional
antibiotic was prescribed in 40 (24%) and 28 (26%) of ertape-
nem and I/M-treated subjects, respectively. The most common
antibiotics were piperacillin/tazobactam (13 subjects), ﬂuo-
roquinolones (12 subjects), polymyxins (12 subjects) and van-
comycin (11 subjects).
Overall, all-cause mortality was 26% (73/279), and 33% (92/
279) subjects were hypoalbuminemic. In subjects treated with
ertapenem, 30-day mortality for severely hypoalbuminemic
subjects was 46% (18/39) compared to 16% (21/134) for sub-
jects with albumin >2.5 g/dL (OR 4.6, 95% CI 2.1–10.1,
p = 0.03). For subjects treated with I/M, 30-day mortality was
35% (18/53) in the low albumin group versus 29% (16/53) in the
higher albumin group; the difference was not statistically sig-
niﬁcant (OR 1.2, 95% CI 0.5–2.7).
Signiﬁcant factors associated with mortality on univariate
analysis in the combined cohort of subjects treated with erta-
penem and I/M included age, SOFA score at presentation,
Charlson score, the type of carbapenem, and serum creatinine
and albumin levels (Table 1). A logistic regression model for
mortality was ﬁtted as described, including these variables and
the interaction between the carbapenem type and albumin
levels (Table 2). Both the carbapenem type and the interaction
between the type of carbapenem and albumin levels were sig-
niﬁcant, indicating that the different associations of the erta-
penem and I/M cohorts with albumin persisted in the adjusted
analysis. According to the model, for each unit decrease in al-
bumin levels there was an increase in 30-day mortality among
subjects treated with ertapenem with an adjusted OR of 2.45
(95% CI 1.19–5.05). In contrast, in subjects treated with I/M,Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infectthe change in albumin level was not signiﬁcantly associated with
mortality (OR 0.67, 95% CI 0.31–1.41). The effect of albumin
levels on 30-day mortality was 3.7 larger with ertapenem
compared to I/M (95% CI 1.4–10.09). The model suggests that
a subject with an albumin level of 4.0 g/dL treated with erta-
penem has a 5% (95% CI 2–13) chance to die within 30 days
compared to a 26% (95% CI 15–42) with an albumin level of
2.0 g/dL, with all other covariates held at mean and median
values (Fig. 1).ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 54–58
CMI Zusman et al. Ertapenem in sepsis with hypoalbuminemia 57DiscussionCarbapenems are used for the treatment of serious infections
in critically ill subjects, including those with poor nutritional
status and hypoalbuminemia. On the basis of earlier pharma-
cokinetic/pharmacodynamic studies, we hypothesized that
ertapenem, being highly protein bound, has reduced effective-
ness in the presence of hypoalbuminemia when used in stan-
dard dosing. Our cohort included 173 subjects treated with I/M
and 106 treated with ertapenem, among whom 40% had
bacteremia and 33% were hypoalbuminemic (albumin 2.5 g/
dL). Hypoalbuminemia had a signiﬁcantly stronger association
with mortality among subjects treated with ertapenem
compared to I/M, and the association was highly signiﬁcant only
in subjects treated with ertapenem. We observed higher crude
30-day mortality with ertapenem compared to I/M for subjects
with hypoalbuminemia, while among subjects with albumin
levels >2.5 g/dL the opposite was true. On multivariable analysis
for 30-day mortality, lower albumin levels were signiﬁcantly and
independently associated with mortality, as was the interaction
between treatment with ertapenem and albumin levels. Using
the regression model we could predict a ﬁve-times-higher
mortality for a subject treated with ertapenem with an albu-
min level of 2 g/dL compared to a subject with normal albumin
(4 g/dL). There was no such association among subjects treated
with I/M.
Possible inferior efﬁcacy in the presence of hypoalbuminemia
is not unique to ertapenem but rather is common to all highly
protein-bound antibiotics such as ceftriaxone, teicoplanin,
aztreonam and daptomycin [24]. Pharmacokinetic studies have
shown that there are large difference in ertapenem unbound
levels between critically ill subjects with severe sepsis andFIG. 1. Probability of 30-day mor-
tality by albumin level in ertapenem-
treated subjects. Probability indi-
cated by solid line, conﬁdence interval
by shading.
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiolohealthy volunteers [12,15]. Examining the clinical consequences
of this difference is difﬁcult because hypoalbuminemia per se is
signiﬁcantly associated with death [18]. In a cohort study
including only subjects treated with ertapenem, we would not
have discerned whether the increase in mortality was due to
hypoalbuminemia by itself or to reduced efﬁcacy of ertapenem
in the presence of hypoalbuminemia. Thus, we decided on a
comparative design, comparing subjects treated with ertape-
nem to subjects treated with other, less protein-bound, car-
bapenems. In this observational design, we had to overcome the
problem that the populations of subjects treated with the
different carbapenems were different; subjects treated with I/M
had higher risk of death at baseline related to higher severity of
illness and more severe sepsis. Thus, we could not directly
compare subjects treated with ertapenem to those treated with
I/M, but we focused instead on the association between treat-
ment, hypoalbuminemia and mortality.
The main limitation of our analysis is the relatively small
sample size, permitting limited adjustment for the comparison
between subject groups. The differences between groups could
have also underlined in part the differences in the associations
between mortality and hypoalbuminemia. Most subjects in the I/
M cohort received meropenem; due to the small size, imipenem
and meropenem could not be analysed separately. Possible
additional factors that might have affected the associations re-
ported and were not investigated include subjects’ weight and
more precise data on antibiotic dosing relative to renal func-
tion. Finally, we did not perform pharmacokinetic analyses.
In a critically ill subject with hypoalbuminemia treated with
carbapenems, should ertapenem or another carbapenem be
used? Our data suggest higher mortality with ertapenem dosed
according to current guidelines. Further studies should evaluate
optimal dosing and administration schedules for ertapenem ingy and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 54–58
58 Clinical Microbiology and Infection, Volume 21 Number 1, January 2015 CMIcritically ill subjects and combine clinical studies with pharma-
cokinetic analyses. Use of ertapenem might have ecological
beneﬁts, but ﬁrst and foremost, we must be sure of the efﬁcacy
of the antibiotic in the target subject population.Transparency DeclarationThis study was supported by internal funding. Findings from this
study were presented at 24th European Congress of Clinical
Microbiology and Infectious Diseases (ECCMID 2014), 10–13
May 2014, Barcelona, Spain. All authors report no conﬂicts of
interest relevant to this article.Appendix A. Supplementary dataSupplementary data related to this article can be found online at
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